文献速递甲状腺与浅表US

热消融治疗自主功能性甲状腺结节的疗效与安全性:系统评价与Meta分析

Efficacy and safety of thermal ablation for autonomously functioning thyroid nodules: a systematic review and meta-analysis.
PubMed 文献 · Eur Radiol · 2020-08-20

该系统评价与Meta分析纳入14项研究、391例患者共411个自主功能性甲状腺结节,评估热消融的疗效与安全性。结果显示促甲状腺激素正常化率为71.2%,平均随访12.8个月时体积缩小率为69.4%,随访期间无患者发生甲状腺功能减退或危及生命的并发症。亚组分析显示结节体积对促甲状腺激素正常化(p=0.54)或体积缩小率(p=0.94)均无显著影响。

要点

  • 热消融治疗自主功能性甲状腺结节后促甲状腺激素正常化率为71.2%,平均随访12.8个月时体积缩小率为69.4%。
  • 随访期间无患者发生甲状腺功能减退或危及生命的并发症。
  • 按结节体积亚组分析,促甲状腺激素正常化(p=0.54)与体积缩小率(p=0.94)均无显著差异。

核心结论

  • 热消融是治疗自主功能性甲状腺结节有效且安全的方法。
  • 结节体积不影响热消融的疗效,该结果应考虑纳入未来的热消融指南。

研究设计与样本

  • 系统评价与Meta分析,检索Ovid-MEDLINE和Embase数据库截至2020年1月6日发表的文献。
  • 纳入14项研究,共391例患者、411个经热消融治疗的自主功能性甲状腺结节。
  • 由两名放射科医生按PRISMA指南进行数据提取和质量评估。
  • 主要结局为促甲状腺激素正常化的汇总比例,次要结局为体积缩小率的汇总估计值。

诊断标准与关键数值

  • 促甲状腺激素正常化率为71.2%。
  • 平均随访12.8个月时体积缩小率为69.4%。
  • 按结节体积亚组分析,促甲状腺激素正常化差异无统计学意义(p=0.54),体积缩小率差异无统计学意义(p=0.94)。

临床应用与阅片要点

  • 对于自主功能性甲状腺结节患者,热消融可作为替代治疗选择,其促甲状腺激素正常化率为71.2%,平均随访12.8个月时体积缩小率为69.4%。
  • 随访期间无患者发生甲状腺功能减退或危及生命的并发症。
  • 结节体积不影响热消融的疗效,该结果应考虑纳入未来的热消融指南。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: Although thermal ablation has been regarded as an alternative treatment option for autonomously functioning thyroid nodules (AFTNs), the efficacy of this treatment in patients with AFTNs has not yet been systematically evaluated. In this systematic review and meta-analysis, we aimed to evaluate the efficacy and safety of thermal ablation in the treatment of AFTN, and identify the factors affecting the effectiveness of the treatment.

METHODS: Ovid-MEDLINE and Embase databases were searched for studies reporting the efficacy and safety of thermal ablation for patients with AFTN published up until January 6, 2020. Data extraction and quality assessment were performed by two radiologists according to PRISMA guidelines. The primary and secondary outcomes were to yield the pooled proportions of thyroid-stimulating hormone (TSH) normalization and pooled estimates of volume reduction rate (VRR), respectively. Subgroup analyses were performed to identify factors affecting the treatment efficacy.

RESULTS: This systematic review identified 411 AFTNs treated by thermal ablation in 391 patients in 14 studies. TSH normalization was achieved in 71.2% of patients and the volume reduction rate was 69.4% at a mean follow-up period of 12.8 months. No patients experienced hypothyroidism or a life-threatening complication during follow-up. Subgroup analyses according to nodule volume did not find a significant difference in TSH normalization (p = 0.54) or VRR (p = 0.94).

CONCLUSIONS: Thermal ablation is an effective and safe treatment method for patients with AFTNs. The nodule volume did not affect the efficacy of thermal ablation, and this result should be considered in future thermal ablation guidelines.

KEY POINTS: • Thermal ablation has good efficacy and safety in the treatment of autonomously functioning thyroid nodule. • The efficacy of thermal ablation was not affected by nodule volume.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Kim HJ, Cho SJ, Baek JH, et al. Efficacy and safety of thermal ablation for autonomously functioning thyroid nodules: a systematic review and meta-analysis. Eur Radiol. 2020. PMID: 32816198. doi:10.1007/s00330-020-07166-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。